Viral Vector and Plasmid DNA Manufacturing Market Size, Share, Growth and Forecast 2019 to 2026

Lehdistötiedotteet   •   Joulu 03, 2019 09:10 EET

The global Viral Vector and Plasmid DNA manufacturing market size is expected to reach USD 2,493.80 million by the year 2026, with a CAGR of 23.8% during the forecast period 2019 to 2026.

Viral and non-viral vectors have emerged as an efficient delivery mechanism for the development of innovative medicines. Viral vectors and plasmid DNA are products of gene therapy, which are used for the treatment of a large number of diseases such as cancer and other chronic disorders. The advantages of gene vaccines and gene therapy over conventional vaccines and therapies include the ability to induce a wide range of immune response types. The major driving factors that are boosting the growth of Viral Vector and Plasmid DNA manufacturing market are the global rise in the incidence of cancer, increase in geriatric population susceptible to diseases, government initiatives & grants and the increase in investment by private companies on R&D activities of viral vectors and plasmid DNA manufacturing.

Customized Requirements? Need a Sample? Please Email us at: sales@visionresearchreports.com

Viral vectors and plasmid DNA can reduce the cost of treatment and help to decrease the repeated administration of medications. Manufacturers in the Viral Vector and Plasmid DNA manufacturing market are increasing the strategic business expansion activities through merger and acquisitions to increase their customer base and enhance the product portfolio which supports the growth of the target market. For instance, In 2019 Aldevron a US based company entered into a long term agreement with Sarepta Therapeutics, Inc., a leader in precision genetic medicine for rare diseases. In this agreement, Aldevron will supply plasmid DNA to fulfill Sarepta's needs for its gene therapy clinical trials and commercial supply. According to an article published by Human Gene Therapy, the acceptance of gene therapy for severe disorders, such as Alzheimer Disease, is high as compared to less severe disease, such as attention deficit hyperactivity disorder.

Factors, such as technological advancements to mitigate challenges posed by conventional methods of vector production, increase in the number of clinical studies, and a growing number of gene therapy candidates, coupled with their rapid progression through various phases of clinical development, are primarily driving the demand for viral vector and plasmid DNA manufacturing market. However, high costs associated with gene therapies is slated to impede the growth of the viral vector and plasmid DNA manufacturing market. Conversely, the surge of the personalized medicine industry is anticipated to provide stellar growth opportunities to the viral vector and plasmid DNA manufacturing market.

The primary indications of Viral Vector and Plasmid DNA manufacturing market are Cancer, Alzheimer and Parkinson’s disease. With respect to the region, the Asia Pacific region is projected to be the highest growing market in Viral Vector and Plasmid DNA manufacturing market during the forecast period, followed by Europe. This market is also anticipated to grow at the highest CAGR of 25.4% during the forecast period. North America was found to be the largest revenue-generating segment due to the high burden increasing cancer and inherited disorders and the due to increase in gene therapy awareness in the region.

Buy this Premium Research Report, Single User Licence US$ 2500 and Multi-user User Licence US$ 4000 Contact Us@ sales@visionresearchreports.com

Further key findings from the report suggest

  • Increasing acceptance of viral vector-based advanced treatments is likely to drive the segment in viral vector and plasmid DNA manufacturing market. The significant share is due to the use of adeno associated virus, lentivirus, and others.
  • By application, cancer is expected to account for the largest share of the market, followed by genetic disorder segment, which occupied a market share of around 33.3% in 2017.
  • The following are the significant genetically modified therapies rigorously studied and analyzed, namely, LUXTURNA, YESCARTA, Kymriah, INVOSSA, Zalmoxis, Strimvelis, Imlygic, Neovasculagen, Rexin-G, Oncorine, and Gendicine. Amongst these, YESCARTA and Kymriah are T-cell based gene therapies that were recently approved by the FDA, in October 2017 and August 2017, respectively. Besides, over 430 gene therapy candidates are presently in different stages of clinical development, for which over 500 clinical studies are currently underway in various regions across the globe.
  • The growing number of gene therapy candidates, coupled with their rapid progression through multiple phases of clinical development, is expected to continue to create an increasing demand for vectors.
  • North America dominates the global viral vector and plasmid DNA manufacturing market due to a large patient pool, and high acceptance of advanced treatments in the region. The region is estimated to maintain its dominance during the forecast period. Moreover, rising healthcare expenditure, availability of approved gene therapy treatments, and increasing investments are key factors that are anticipated to boost the viral vector and plasmid DNA manufacturing market in the next few years.
  • The viral vector and plasmid DNA manufacturing market in the Asia Pacific is projected to expand at a notable CAGR due to increasing awareness regarding viral vector-based products in developing countries and rising research initiatives in countries such as Japan and China.
  • FUJIFILM Diosynth Biotechnologies, Kaneka Eurogentec S.A, Fin vector, Spark therapeutics, Cobra biologics, Cell and gene therapy catapult, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Ltd, Thermo Fisher Scientific, Inc, 4D Molecular Therapeutics are the major players in the Viral vector and plasmid DNA manufacturing market.

In this study, the years considered to estimate the market size of viral vector and plasmid DNA manufacturing are as follows:

  • History Year: 2015-2018
  • Base Year: 2018
  • Estimated Year: 2019
  • Forecast Year 2019 to 2026

Segments covered in the report:

This report forecasts revenue growth at a global, regional & country level, and provides an analysis of the industry trends in each of the sub-segments from 2016 to 2026. For the purpose of this study, Reports and Data have segmented the viral vector and Plasmid DNA manufacturing market into product types, application types, end user, workflow, sales channel and region.

By Product

  • Plasmid DNA
  • Viral Vectors
  • Non-viral Vectors

By Workflow

  • Upstream Processing
    • Vector Amplification & Expansion
    • Vector Recovery/Harvesting
  • Downstream Processing
    • Purification
    • Fill-finish

By Disease

  • Cancer
  • Inherited Disorders
  • Viral Infections
  • Others

By Application

  • Antisense, RNAi, & Molecular Therapy
  • Vaccinology

By Sales channel

  • Channel sales
  • Direct Sales

By End user

  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes

Regional Outlook

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Rest of the Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia-Pacific
  • Middle East & Africa
    • Latin America
  • Brazil

Table of Content

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Viral Vector & Plasmid DNA Manufacturing
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Viral Vector & Plasmid DNA Manufacturing Market By Type
1.2.2.1. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.2.2. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue Share By Type in 2017
1.2.2.3. Lentivirus
1.2.2.4. Adenovirus
1.2.2.5. Plasmid DNA
1.2.2.6. Adeno-Associated Virus
1.2.2.7. Others
1.2.3. Viral Vector & Plasmid DNA Manufacturing Market By Application
1.2.3.1. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By Application (2015-2026)
1.2.3.2. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue Share By Application in 2017
1.2.3.3. Gene Therapy
1.2.3.4. Vaccinology
1.2.4. Viral Vector & Plasmid DNA Manufacturing Market By Disease
1.2.4.1. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By Disease (2015-2026)
1.2.4.2. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue Share By Disease in 2017
1.2.4.3. Infectious Disease
1.2.4.4. Genetic Disorders
1.2.4.5. Cancer
1.2.4.6. Others
1.2.5. Viral Vector & Plasmid DNA Manufacturing Market By End Use
1.2.5.1. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By End Use (2015-2026)
1.2.5.2. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue Share By End Use in 2017
1.2.5.3. Research Institutes
1.2.5.4. Biotech Companies
1.2.5.5. Others
1.2.6. Viral Vector & Plasmid DNA Manufacturing Market by Geography
1.2.6.1. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.6.2. North America Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
1.2.6.3. Europe Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
1.2.6.4. Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
1.2.6.5. Latin America Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
1.2.6.6. Middle East and Africa (MEA) Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Viral Vector & Plasmid DNA Manufacturing Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Viral Vector & Plasmid DNA Manufacturing Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Viral Vector & Plasmid DNA Manufacturing Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Viral Vector & Plasmid DNA Manufacturing Major Manufacturers in 2017

CHAPTER 4. Viral Vector & Plasmid DNA Manufacturing Market By Type

4.1. Global Viral Vector & Plasmid DNA Manufacturing Revenue By Type
4.2. Lentivirus
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Adenovirus
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Plasmid DNA
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Adeno-Associated Virus
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Others
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. Viral Vector & Plasmid DNA Manufacturing Market By Application

5.1. Global Viral Vector & Plasmid DNA Manufacturing Revenue By Application
5.2. Gene Therapy
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Vaccinology
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Others
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. Viral Vector & Plasmid DNA Manufacturing Market By Disease

6.1. Global Viral Vector & Plasmid DNA Manufacturing Revenue By Disease
6.2. Infectious Disease
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Genetic Disorders
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Cancer
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Others
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. Viral Vector & Plasmid DNA Manufacturing Market By End Use

7.1. Global Viral Vector & Plasmid DNA Manufacturing Revenue By End Use
7.2. Research Institutes
7.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.3. Biotech Companies
7.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.4. Others
7.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 8. North America Viral Vector & Plasmid DNA Manufacturing Market By Country

8.1. North America Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. North America Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. U.S.
8.3.1. U.S. Viral Vector & Plasmid DNA Manufacturing Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.4. Canada
8.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.5. Mexico
8.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 9. Europe Viral Vector & Plasmid DNA Manufacturing Market By Country

9.1. Europe Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Europe Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. UK
9.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.4. Germany
9.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.5. France
9.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.6. Spain
9.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.7. Rest of Europe
9.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 10. Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Market By Country

10.1. Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. China
10.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.4. Japan
10.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.5. India
10.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.6. Australia
10.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.6.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.7. South Korea
10.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.7.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.8. Rest of Asia-Pacific
10.8.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.8.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 11. Latin America Viral Vector & Plasmid DNA Manufacturing Market By Country

11.1. Latin America Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Latin America Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Brazil
11.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
11.4. Argentina
11.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
11.5. Rest of Latin America
11.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 12. Middle East Viral Vector & Plasmid DNA Manufacturing Market By Country

12.1. Middle East Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Middle East Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. Saudi Arabia
12.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
12.4. UAE
12.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
12.5. Rest of Middle East
12.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 13. Africa Viral Vector & Plasmid DNA Manufacturing Market By Country

13.1. Africa Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 - 2026 ($Million)
13.2. Africa Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
13.3. South Africa
13.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
13.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
13.4. Egypt
13.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
13.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
13.5. Rest of Africa
13.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
13.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 14. COMPANY PROFILE

14.1. CobraBiologics
14.1.1. Company Snapshot
14.1.2. Overview
14.1.3. Financial Overview
14.1.4. Product Portfolio
14.1.5. Key Developments
14.1.6. Strategies
14.2. Novasep
14.2.1. Company Snapshot
14.2.2. Overview
14.2.3. Financial Overview
14.2.4. Product Portfolio
14.2.5. Key Developments
14.2.6. Strategies
14.3. Spark Therapeutics, Inc.
14.3.1. Company Snapshot
14.3.2. Overview
14.3.3. Financial Overview
14.3.4. Product Portfolio
14.3.5. Key Developments
14.3.6. Strategies
14.4. FUJIFILM Diosynth Ltd
14.4.1. Company Snapshot
14.4.2. Overview
14.4.3. Financial Overview
14.4.4. Product Portfolio
14.4.5. Key Developments
14.4.6. Strategies
14.5. Cell and Gene Therapy Catapult
14.5.1. Company Snapshot
14.5.2. Overview
14.5.3. Financial Overview
14.5.4. Product Portfolio
14.5.5. Key Developments
14.5.6. Strategies
14.6. Kaneka Eurogentec, Inc.
14.6.1. Company Snapshot
14.6.2. Overview
14.6.3. Financial Overview
14.6.4. Product Portfolio
14.6.5. Key Developments
14.6.6. Strategies
14.7. Merck KGaA
14.7.1. Company Snapshot
14.7.2. Overview
14.7.3. Financial Overview
14.7.4. Product Portfolio
14.7.5. Key Developments
14.7.6. Strategies
14.8. Lonza
14.8.1. Company Snapshot
14.8.2. Overview
14.8.3. Financial Overview
14.8.4. Product Portfolio
14.8.5. Key Developments
14.8.6. Strategies
14.9. UniQure N.V.
14.9.1. Company Snapshot
14.9.2. Overview
14.9.3. Financial Overview
14.9.4. Product Portfolio
14.9.5. Key Developments
14.9.6. Strategies
14.10. Others
14.10.1. Company Snapshot
14.10.2. Overview
14.10.3. Financial Overview
14.10.4. Product Portfolio
14.10.5. Key Developments
14.10.6. Strategies

CHAPTER 15. RESEARCH APPROACH

15.1. Research Methodology
15.1.1. Initial Data Search
15.1.2. Secondary Research
15.1.3. Primary Research

15.2. Assumptions and Scope

Buy this Premium Research Report, Single User Licence US$ 2500 and Multi-user User Licence US$ 4000 Contact Us@ sales@visionresearchreports.com

Global Viral Vector and Plasmid DNA manufacturing market size is expected to reach USD 2,493.80 million by the year 2026, with a CAGR of 23.8% during the forecast period 2019 to 2026.

Lue lisää »

Business Intelligence: GE Healthcare launches new program to simplify AI development, implementation

Lehdistötiedotteet   •   Marras 27, 2019 13:00 EET

Healthcare Research Study

Healthcare Research Study

Healthcare Industry Research, M&A Activity, Innovation and More.